

Pulmonary Arterial Hypertension

Revatio® (sildenafil), Remodulin® (treprostinil), Flolan®/ Veletri® (epoprostenol), Uptravi® (selexipag) (Intravenous/Subcutaneous)

Document Number: IC-0416

Last Review Date: 01/05/2023

Date of Origin: 11/28/2011

Dates Reviewed: 12/2011, 02/2013, 06/2013, 11/2013, 12/2013, 04/2014, 02/2015, 01/2016, 01/2017, 05/2017, 09/2017, 01/2018, 01/2019, 01/2020, 01/2021, 09/2021, 01/2022, 01/2023

I. Length of Authorization ¹

Coverage will be provided for 6 months and is eligible for renewal.

Uptravi and Revatio only: Coverage will be provided for 1 month and is eligible for renewal.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

Drug	Drug strength/formulation	# of Units	Per # of Days	Units/Day
Revatio	10 mg/12.5 mL injection	90 vials	30	3 vials
Flolan/Veletri	0.5 mg injection 1.5 mg injection	60 vials	30	2 vials
Epoprostenol (generic Flolan)	0.5 mg injection 1.5 mg injection	60 vials	30	2 vials
Remodulin	1 mg/mL – 20 mg injection 2.5 mg/mL – 50 mg injection 5 mg/mL – 100 mg injection 10 mg/mL – 200 mg injection 20 mg/mL – 40 mg injection	20 mL (1 vial)	30	0.67 mL
Treprostinil	1 mg/mL- 20 mg injection 2.5 mg/mL- 50 mg injection 5 mg/mL- 100 mg injection 10 mg/mL- 200 mg injection	20 mL (1 vial)	30	0.67 mL
Uptravi	1800 mcg/10mL injection	60 vials	30	2 vials

B. Max Units (per dose and over time) [HCPCS Unit]:

Flolan/Veletri/Epoprostenol

- 6 billable units per day

Remodulin/Treprostinil

- 7 billable units per day

Revatio

- 30 mg per day

Uptravi

- 3600 mcg per day

III. Initial Approval Criteria ¹⁻⁵

Coverage is provided in the following conditions:

- Patient is at least 18 years of age (unless otherwise specified);
 - Patient is at least 17 years of age for Remodulin; **AND**

Universal Criteria ²⁻⁵

- Patient will NOT receive concomitant treatment with organic nitrates (i.e., isosorbide mononitrate, isosorbide dinitrate, nitroglycerin) or riociguat (**Revatio ONLY**); **AND**
- Patient does not have heart failure with reduced left ventricular ejection fraction (**Flolan ONLY**); **AND**
- Patient does not have congestive heart failure due to severe left ventricular systolic dysfunction OR pulmonary edema (**Veletri ONLY**); **AND**
- Patient will NOT receive concomitant treatment with strong CYP2C8 inhibitors (e.g., gemfibrozil) (**Uptravi ONLY**); **AND**

Pulmonary Arterial Hypertension (PAH) † Φ ^{27,28,30}

- Diagnosis confirmed by documented right heart catheterization with ALL of the following:
 - Mean pulmonary artery pressure (mPAP) > 20 mm Hg; **AND**
 - Pulmonary arterial wedge pressure (PAWP) \leq 15 mmHg; **AND**
 - Pulmonary vascular resistance (PVR) \geq 3 wood units (240 dynes-sec/cm⁵); **AND**
- Baseline assessment of 6-minute walk distance (6MWD), brain natriuretic peptide (BNP) plasma levels, and/or B-type natriuretic peptide plasma levels (NT-proBNP); **AND**
- Diagnosed with pulmonary arterial hypertension and classified as WHO (World Health Organization) Group 1 (See below for description of WHO classification for pulmonary hypertension); **AND**
- Designated as New York Heart Association (NYHA) or World Health Organization (WHO) functional class II-IV (See below for description of functional classes); **AND**
 - Patient is treatment-naïve to PAH-specific pharmacotherapy **§**; **AND**
 - Patient is Functional Class II or Functional Class III without evidence of rapid disease progression or poor prognosis; **AND**
 - Patient had an inadequate response to calcium channel blocker therapy or is not a candidate for treatment with a calcium channel blocker (i.e., negative results for acute vasoreactivity, right ventricular failure, or contraindication to calcium channel blocker); **AND**
 - Patient is unwilling or unable to tolerate combination therapy; **AND**
 - Patient will be treated with Revatio monotherapy; **OR**

- Patient is Functional Class III with evidence of rapid progression of their disease, or other markers of a poor clinical prognosis; **AND**
 - Patient will be treated with continuous IV Flolan or Veletri; **OR**
 - Patient will be treated with IV or SC Remodulin; **OR**
- Patient is Functional Class IV; **AND**
 - Patient will be treated with continuous IV Flolan or Veletri; **OR**
 - Patient will be treated with IV or SC Remodulin; **OR**
- Patient is Functional Class III or IV and had an inadequate clinical response‡ (see criteria below) to monotherapy and will be adding a second class of PAH therapy as one of the following (see PAH pharmacotherapy table below §):
 - Adding Revatio to an intravenous epoprostenol; **OR**
 - Initiating an up-titration of the patient’s current dose of IV Flolan or Veletri; **OR**
- Patient is Functional Class III or IV with an inadequate clinical response‡ (see criteria below) to two classes of PAH pharmacotherapy and will be adding a third class of PAH therapy (see PAH pharmacotherapy table below §); **OR**
- Patient is transitioning from Remodulin to Orenitram and using Remodulin (treprostinil) and Orenitram (treprostinil) concurrently; **OR**
- Patient is transitioning from epoprostenol to Remodulin (treprostinil); **OR**
- Patient is temporarily unable to take **oral** Uptravi therapy (**Uptravi ONLY**); **OR**
- Patient is temporarily unable to take **oral** Revatio therapy (**Revatio ONLY**)

Pulmonary Hypertension Pharmacotherapy § 2,5,27		
Class	Drug	Route of Administration
Phosphodiesterase-5 inhibitors (PDE5i)	Revatio (Sildenafil) Adcirca (Tadalafil) Tadliq (Tadalafil)	IV, Oral Oral Oral
Prostacyclin analogs	Flolan (Epoprostenol) Veletri (Epoprostenol) Orenitram (Treprostinil) Remodulin (Treprostinil) Tyvaso/Tyvaso DPI (Treprostinil) Ventavis (Iloprost)	IV IV Oral IV/SC Inhaled Inhaled
Endothelial-receptor antagonists (ERA)	Tracleer (Bosentan) Letairis (Ambrisentan) Opsumit (Macitentan)	Oral Oral Oral
Soluble guanylate cyclase stimulators	Adempas (riociguat) <ul style="list-style-type: none"> ▪ Must NOT be used in combination with PDE5i (e.g., Revatio, Adcirca, Tadliq) or intravenous prostacyclin analogs (e.g., Flolan, Veletri, Remodulin) ▪ <i>Subcutaneous administration of Remodulin is allowable with Adempas</i> 	Oral
Prostacyclin receptor agonists	Uptravi (selexipag) <ul style="list-style-type: none"> ▪ May be used in combination with BOTH a PDE5i AND an ERA 	Oral, IV

Inadequate Clinical Response Criteria †¹³

- Inadequate clinical response for patients who were initially in WHO Functional Class II or III:
 - Resulting clinical status defined as stable and not satisfactory; **OR**
 - Resulting clinical status defined as unstable and deteriorating
- Inadequate clinical response for patients who were initially in WHO Functional Class IV:
 - No rapid improvement to WHO Functional Class III or better; **OR**
 - Resulting clinical status defined as stable and not satisfactory

Reference charts^{27,29}

WHO Classification of Pulmonary Hypertension (PH):

- Group 1 PAH: Pulmonary arterial hypertension (PAH)
- Group 2 PH: Pulmonary hypertension owing to left heart disease
- Group 3 PH: Pulmonary hypertension owing to lung diseases and/or hypoxia
- Group 4 PH: Chronic thromboembolic pulmonary hypertension (CTEPH)
- Group 5 PH: Pulmonary hypertension with unclear multifactorial mechanisms

New York Heart Association (NYHA) Functional Classification

- Class I: No symptoms with ordinary physical activity. No limitation of physical activity. Comfortable at rest.
- Class II: Symptoms with ordinary physical activity. Slight limitation of physical activity. Comfortable at rest.
- Class III: Symptoms with less than ordinary physical activity. Marked limitation of physical activity. Comfortable at rest.
- Class IV: Symptoms with any physical activity or even at rest. Unable to perform any physical activity.

World Health Organization (WHO) Functional Assessment Classification

- Class I: Patients with PH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope.
- Class II: Patients with PH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
- Class III: Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope.
- Class IV: Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right-heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

† FDA-labeled indication(s); Ⓞ Orphan Drug (*Flolan, Remodulin, and Uptravi only*)

Note: Clinical review for use in pediatric patients, unless specified above, will occur on a case by case basis

IV. Renewal Criteria^{1-8,15,22-28,30}

Coverage can be renewed based on the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. in section III; **AND**
- Disease response as determined by one or more of the following:

- Progress towards an improvement in WHO functional class status
- Improvement in right ventricular function (based on echocardiogram or cardiac MRI)
- Improvement (from baseline) on the 6-minute walk distance (6MWD)
- Improvement (from baseline) in B-type natriuretic peptide plasma levels (NT-proBNP);
- Improvement (from baseline) in brain natriuretic peptide (BNP) plasma levels; **AND**

Revatio®²

- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: pulmonary edema, worsening of pulmonary veno-occlusive disease (PVOD), hearing loss, visual loss, hypotension, epistaxis, priapism, etc.; **AND**
- Patient continues to be temporarily unable to take oral Revatio therapy

Flolan®, Veletri®^{3,5}

- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: increased risk of bleeding, pulmonary edema, vasodilation reactions (hypotension, flushing, nausea, vomiting, dizziness, or headache), etc.

Remodulin®¹

- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: catheter-related blood stream infections (BSIs), sepsis, symptomatic hypotension, increased risk of bleeding, etc.

Uptravi®⁵

- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: pulmonary edema/pulmonary veno-occlusive disease (PVOD), etc.; **AND**
- Patient continues to be temporarily unable to take oral Uptravi therapy

V. Dosage/Administration¹⁻⁵

Indication	Dose
Revatio® (intravenous injection)	2.5 mg or 10 mg (12.5 mL) three times a day administered as an intravenous bolus injection
Flolan®/ Veletri® (continuous intravenous infusion)	Initiate at 2 ng/kg/min. Increase infusion by 1- to 2-ng/kg/min increments every 15 minutes or longer until dose-limiting pharmacologic effects are elicited or until a tolerance limit to the drug is established. Epoprostenol must be infused via a central venous catheter.
Remodulin® (continuous subcutaneous)	1.25 ng/kg/min (or 0.625 ng/kg/min if not tolerated or in patients with mild or moderate hepatic insufficiency); dose increase based on clinical response (increments

Indication	Dose																		
or intravenous infusion)	of 1.25 ng/kg/min per week for the first 4 weeks of treatment, then 2.5 ng/kg/min per week for the remaining duration of the infusion). <u>Transitioning from epoprostenol:</u> <ul style="list-style-type: none"> Initiate Remodulin at a recommended dose of 10% of the current epoprostenol dose Decrease the dose of epoprostenol while simultaneously increasing the dose of Remodulin, based on response 																		
Uptravi® (continuous intravenous infusion)	Administer twice daily for patients who are temporarily unable to take oral therapy at a dose that corresponds to the patient's current dose of UPTRAVI oral tablets (see below) <table border="1"> <thead> <tr> <th>UPTRAVI tablets dose (mcg) for twice daily dosing</th> <th>Corresponding IV UPTRAVI Dose (mcg) for twice daily dosing</th> </tr> </thead> <tbody> <tr> <td>200</td> <td>225</td> </tr> <tr> <td>400</td> <td>450</td> </tr> <tr> <td>600</td> <td>675</td> </tr> <tr> <td>800</td> <td>900</td> </tr> <tr> <td>1000</td> <td>1125</td> </tr> <tr> <td>1200</td> <td>1350</td> </tr> <tr> <td>1400</td> <td>1575</td> </tr> <tr> <td>1600</td> <td>1800</td> </tr> </tbody> </table>	UPTRAVI tablets dose (mcg) for twice daily dosing	Corresponding IV UPTRAVI Dose (mcg) for twice daily dosing	200	225	400	450	600	675	800	900	1000	1125	1200	1350	1400	1575	1600	1800
UPTRAVI tablets dose (mcg) for twice daily dosing	Corresponding IV UPTRAVI Dose (mcg) for twice daily dosing																		
200	225																		
400	450																		
600	675																		
800	900																		
1000	1125																		
1200	1350																		
1400	1575																		
1600	1800																		

VI. Billing Code/Availability Information

Drug	HCPCS Code	Billable Units (BU)	Drug strength/formulation	NDC
Revatio* (Pfizer)	J3490 C9399 (<i>Hospital outpatient use only</i>)	N/A	10 mg/12.5mL injection	00069-0338-xx
Flolan* (GSK)	J1325§	0.5 mg = 1 BU	0.5 mg injection	00173-0517-xx
			1.5 mg injection	00173-0519-xx
Veletri* (Actelion Pharm)	J1325§	0.5 mg = 1 BU	0.5 mg injection	66215-0403-xx
			1.5 mg injection	66215-0402-xx
Remodulin* (United Therapeutics)	J3285§	1 mg = 1 BU	1 mg/mL – 20 mg injection	66302-0101-xx
			2.5 mg/mL – 50 mg injection	66302-0102-xx
			5 mg/mL – 100 mg injection	66302-0105-xx
			10 mg/mL – 200 mg injection	66302-0110-xx
			20 mg/mL – 400 mg injection	66302-0120-xx
Uptravi (Actelion Pharmaceuticals)	J3490 C9399 (<i>Hospital outpatient use only</i>)	N/A	1800 mcg/10mL injection	66215-0718-xx

* *Generic available*

§ *Sterile diluent for epoprostenol, 50mL, should be billed under HCPCS code S0155 or J3490*

VII. References

1. Remodulin [package insert]. Research Triangle Park, NC; United Therapeutics Corp.; July 2021. Accessed December 2022.
2. Revatio [package insert]. New York, NY; Pfizer, Inc.; February 2020. Accessed December 2022.
3. Flolan [package insert]. Research Triangle Park, NC; GlaxoSmithKline; August 2021. Accessed December 2022.
4. Veletri [package insert]. South San Francisco, CA; Actelion Pharmaceuticals; July 2022. Accessed December 2022.
5. Uptravi [package insert]. South San Francisco, CA; Actelion Pharmaceuticals US, INC.; July 2022. Accessed December 2022.
6. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med* 1996 Feb 1; 334(5):296-302.
7. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med* 2002 Mar 15; 165(6):800-4.
8. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. *Chest*. 2007 Sep; 132(3):757-63.
9. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest* 2004 Jul; 126(1 Suppl):35S-62S.
10. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. *Chest* 2007 Jun; 131(6):1917-28.
11. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation* 2009; 28:119:2250-94.
12. McCrory DC, Coeytaux RR, Schmit KM, et al. Pulmonary Arterial Hypertension: Screening, Management, and Treatment [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr.
13. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2009; 30(20):2493-537.

14. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J*. 2004; 24:353–9.
15. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med*. 2008; 149:521–30.
16. Keogh A, Strange G, Kotlyar E, et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. *Intern Med J*. 2011; 41(3):235-44.
17. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. *Eur Respir J* 2007; 29: 469–475.
18. Hoepfer MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. *Eur Respir J* 2004; 24: 1007–1010.
19. Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. *Circulation*. 2015 Nov 24; 132(21):2037-99.
20. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. *J Am Coll Cardiol*. 2013 Dec 24; 62(25 Suppl):D73-81.
21. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. *Rev Esp Cardiol (Engl Ed)*. 2016 Feb; 69(2):177.
22. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults, CHEST Guideline and Expert Panel Report. *Chest*. 2014 Aug; 146(2): 449-475.
23. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. *Chest*. 2011 Nov;140(5):1274-1283. doi: 10.1378/chest.10-0969. Epub 2011 May 5.
24. Vizza CD, Sastry BK, Safdar Z, et al. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. *BMC Pulm Med*. 2017 Feb 23;17(1):44. doi: 10.1186/s12890-017-0374-x.
25. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med*. 2000 Mar 21;132(6):425-34.
26. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). *Am Heart J*. 1997 Jul;134(1):44-54.
27. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. *Chest*. 2019 Mar;155(3):565-586. doi: 10.1016/j.chest.2018.11.030.
28. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J*. 2019;53(1):1801913. Published 2019 Jan 24. doi:10.1183/13993003.01913-2018.

29. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed, Little, Brown & Co, Boston 1994. p.253.
30. Humbert M, Kovacs G, Hoeper M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Heart Journal* (2022) 43, 3618–3731. <https://doi.org/10.1093/eurheartj/ehac237>.

Appendix 1 – Covered Diagnosis Codes

ICD-10	Description
I27.0	Primary pulmonary hypertension
I27.1	Kyphoscoliotic heart disease
I27.20	Pulmonary hypertension, unspecified
I27.21	Secondary pulmonary arterial hypertension
I27.83	Eisenmenger's syndrome
I27.89	Other specified pulmonary heart diseases
I27.9	Pulmonary heart disease, unspecified
M34.0	Progressive systemic sclerosis
M34.1	CR(E)ST syndrome
M34.9	Systemic sclerosis, unspecified

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC